Aura Biosciences (AURA) vs Iambic Therapeutics (IAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aura Biosciences is the larger company by market cap ($715.0 million vs $621.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | IAM |
|---|---|---|
| Share price | $6.87 | $13.11 |
| Market cap | $714.99M | $621.42M |
| 1-day change | -1.58% | -8.06% |
| YTD return | +26.06% | — |
| 1-year return | +26.29% | — |
| 5-year return | -69.63% | — |
| EPS (TTM) | $-1.59 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-106.19M | — |
| 52-week high | $9.54 | $25.00 |
| 52-week low | $4.73 | $9.60 |
| Distance from 52-week high | -27.95% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +141.63% | +107.86% |
| Average volume | 847.22K | 714.92K |
| Shares outstanding | 104.07M | 47.40M |
| Employees | 113 | 171 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Iambic Therapeutics
IAM stock →Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees
AURA vs IAM FAQ
Which is bigger, Aura Biosciences or Iambic Therapeutics?
Aura Biosciences (AURA) is larger, with a market capitalization of $714.99M compared with $621.42M for Iambic Therapeutics (IAM).
Are Aura Biosciences and Iambic Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.